Launched Niagen™ Plus Niagen™ Liquid At-Home Injections
Launched Niagen NanoCloud™, the first dermatologist-tested topical product
Launched “Don’t Get Old.
Net sales of
Generated
Third Quarter 2026 Financial and Business Highlights
- Total net sales of
$27.2 million , including$23.3 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 13% year-over-year. - Gross margin of 62.9%, which the Company believes reflects the strength of its operational foundation.
- Net loss of
$1.2 million , with basic and diluted loss per share of$(0.01) . - Adjusted EBITDA, a non-GAAP measure, was positive at
$0.5 million . - Total cash provided by operations of
$4.2 million during the nine months endedSeptember 30, 2026 , and$2.6 million in the three-month period. - The Company ended the quarter with
$69.5 million in cash and cash equivalents, as compared to$66.7 million in cash and cash equivalents for the period endedJune 30, 2026 . - Launched the liquid, ready-to-inject Niagen™ At-Home Injection Kit, formulated with pharmaceutical grade Niagen nicotinamide riboside (NR) through the Niagen™ Plus telehealth platform.
- Launched Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line. The inaugural product in this new category is Niagen NanoCloud™, the first dermatologist-tested topical product powered by Niagen NR.
- Launched “Don't Get Old. Age Better®,” a new brand campaign for the Niagen® brand and sub-brands Tru Niagen® and Niagen Plus™, featuring 11-time world champion surfer
Kelly Slater and more than 20 partners, across sports, entertainment, and medicine. - Announced a Start-Up Agreement with
Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen to date. NAD Pharmaceuticals engagedRed Sky Partners , a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug candidate, targeting rare genetic diseases and aging-related disorders.- Expanded access to Tru Niagen by launching on
Walmart.com and diversified the e-commerce marketplace presence and expanded retail footprint by launching at nearly 300 GNC and Sam’s Club locations across 44 states combined. - Announced the publication of a new peer-reviewed analysis of past clinical studies in Aging Cell examining the effects of Niagen® supplementation was associated with reduced muscle epigenetic age acceleration measured by the Muscle Epigenetic
Age Test (MEAT) clock.
“During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and
2026 Outlook and Strategic Priorities:
For the full year 2026, the Company expects direct website revenues to grow by 15% to 20% year-over-year and overall e-commerce to grow by approximately 5% year-over-year. The Company expects the performance of the remainder of its consumer business to offset the growth of the e-commerce business. The ingredient business is expected to be lower than the prior year, primarily due to decreased volume from key ingredient partners due to competitive market dynamics, although additional ingredient partners were added in Q3 2026 and more are expected to be added in the near term. The Company is planning to introduce a lower-cost NR salt form, patented by
The Company believes 2026 is an important year of strategic investment and continues to expect operating expenses to increase as it invests across commercial, research and administrative functions to support these strategic priorities, while continuing to focus on disciplined capital allocation and positive cash flow from operations.
Investor Conference Call
A live webcast will be held
To listen to the webcast, or to view the earnings press release and its accompanying financial exhibits, please visit the Investor Relations section of Niagen Bioscience’s website at https://investors.niagenbioscience.com. The toll-free dial-in information for this call is 1-833-461-5787 with Conference ID: 198389474. The webcast will be recorded, and will be available for replay via the website from
Important Note on Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could,” “predicts,” “projects,” “continues,” “would” or the negative of such terms or other similar expressions. Forward-looking statements include without limitation, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the quotation from Niagen Bioscience’s Chief Executive Officer, statements related to the Company’s 2026 financial outlook including but not limited to net sales, gross margin, expenses, investment priorities, and commercialization efforts and statements regarding Niagen® and Niagen Plus clinical initiatives and statements attributable to management.
Risks that contribute to the uncertain nature of the forward-looking statements include: our relationships with major customers; a decline in general economic conditions nationally and internationally; the market and size of the vitamin, mineral and dietary supplement market and the intravenous market; decreased demand for our products and services; market acceptance of our products; the success of our brand campaign and other marketing investments; interruptions in our ability to sell products through third-party online marketplaces; the ability to protect our intellectual property rights; impact of any litigation or infringement actions brought against us; regulation of our advertising, marketing and sales practices by the
About
The Company markets its consumer supplement Tru Niagen® and develops and supplies Niagen® as a proprietary ingredient to partners across the health and wellness and pharmaceutical sectors.
Unaudited Condensed Consolidated Statements of Operations | ||||||||||||
| Three Months Ended |
| Nine Months Ended | |||||||||
|
| 2026 |
|
| 2025 |
| 2026 |
| 2025 | |||
(In thousands, except per share data) |
|
|
|
|
|
|
| |||||
Sales, net | $ | 27,192 |
|
| $ | 33,986 |
| $ | 88,451 |
| $ | 95,584 |
Cost of sales |
| 10,087 |
|
|
| 12,058 |
|
| 32,056 |
|
| 34,099 |
Gross profit |
| 17,105 |
|
|
| 21,928 |
|
| 56,395 |
|
| 61,485 |
Operating expenses: |
|
|
|
|
|
|
| |||||
Sales and marketing |
| 8,713 |
|
|
| 8,768 |
|
| 28,518 |
|
| 25,092 |
Research and development |
| 1,796 |
|
|
| 1,795 |
|
| 4,790 |
|
| 4,620 |
General and administrative |
| 8,183 |
|
|
| 7,129 |
|
| 22,398 |
|
| 19,580 |
Total operating expenses |
| 18,692 |
|
|
| 17,692 |
|
| 55,706 |
|
| 49,292 |
Operating income (loss) |
| (1,587 | ) |
|
| 4,236 |
|
| 689 |
|
| 12,193 |
|
|
|
|
|
|
|
| |||||
Nonoperating income: |
|
|
|
|
|
|
| |||||
Interest income, net |
| 414 |
|
|
| 564 |
|
| 1,161 |
|
| 1,575 |
Gain on sale of operating segment |
| — |
|
|
| — |
|
| 4,781 |
|
| — |
|
|
|
|
|
|
|
| |||||
Income (loss) before provision for income taxes |
| (1,173 | ) |
|
| 4,800 |
|
| 6,631 |
|
| 13,768 |
Provision for income taxes |
| — |
|
|
| 222 |
|
| 523 |
|
| 518 |
Net income (loss) | $ | (1,173 | ) |
| $ | 4,578 |
| $ | 6,108 |
| $ | 13,250 |
|
|
|
|
|
|
|
| |||||
Net income (loss) per share attributable to common stockholders: |
|
|
|
|
|
|
| |||||
Basic | $ | (0.01 | ) |
| $ | 0.06 |
| $ | 0.08 |
| $ | 0.17 |
Diluted | $ | (0.01 | ) |
| $ | 0.05 |
| $ | 0.07 |
| $ | 0.15 |
|
|
|
|
|
|
|
| |||||
Weighted average common shares outstanding: |
|
|
|
|
|
|
| |||||
Basic |
| 79,149 |
|
|
| 79,779 |
|
| 79,460 |
|
| 78,953 |
Diluted |
| 79,149 |
|
|
| 86,619 |
|
| 82,822 |
|
| 85,487 |
Unaudited Condensed Consolidated Balance Sheets | |||||
(In thousands) |
| ||||
Assets |
|
|
| ||
Current assets: |
|
|
| ||
Cash and cash equivalents, including restricted cash of | $ | 69,509 |
| $ | 64,788 |
Trade receivables, net of allowances of |
| 6,840 |
|
| 9,741 |
Inventories |
| 20,524 |
|
| 20,424 |
Assets held for sale |
| — |
|
| 541 |
Prepaid expenses and other assets |
| 3,342 |
|
| 1,312 |
Total current assets |
| 100,215 |
|
| 96,806 |
|
|
|
| ||
Leasehold improvements and equipment, net |
| 1,216 |
|
| 1,323 |
Intangible assets, net |
| 5,136 |
|
| 5,660 |
Right-of-use assets, net |
| 1,657 |
|
| 2,192 |
Other long-term assets |
| 470 |
|
| 425 |
Total assets | $ | 108,694 |
| $ | 106,406 |
|
|
|
| ||
Liabilities and Stockholders' Equity |
|
|
| ||
Current liabilities: |
|
|
| ||
Accounts payable | $ | 11,503 |
| $ | 10,796 |
Accrued expenses |
| 3,933 |
|
| 7,722 |
Current maturities of operating lease obligations |
| 799 |
|
| 1,002 |
Current deferred consideration liability |
| 535 |
|
| — |
Customer deposits |
| 137 |
|
| 399 |
Total current liabilities |
| 16,907 |
|
| 19,919 |
Deferred revenue |
| 2,162 |
|
| 2,674 |
Operating lease obligations, less current maturities |
| 1,278 |
|
| 1,815 |
Deferred consideration liability, less current portion |
| 5,273 |
|
| 5,465 |
Total stockholders’ equity |
| 83,074 |
|
| 76,533 |
Total liabilities and stockholders’ equity | $ | 108,694 |
| $ | 106,406 |
Unaudited Condensed Consolidated Statements of Cash Flows | |||||||
| Nine Months Ended | ||||||
(In thousands) |
| 2026 |
|
|
| 2025 |
|
Net cash provided by / (used in): |
|
|
| ||||
Operating activities | $ | 4,203 |
|
| $ | 12,825 |
|
Investing activities |
| 5,101 |
|
|
| (191 | ) |
Financing activities |
| (4,583 | ) |
|
| 6,996 |
|
Net increase in cash and cash equivalents |
| 4,721 |
|
|
| 19,630 |
|
Cash and cash equivalents beginning of period |
| 64,788 |
|
|
| 44,660 |
|
Cash and cash equivalents at end of period | $ | 69,509 |
|
| $ | 64,290 |
|
Unaudited Reconciliation of Non-GAAP Financial Measures | |||||||||||||||||||
Reconciliation of Net Income to Adjusted EBITDA | |||||||||||||||||||
(In thousands) | Q3 2026 |
| Q2 2026 |
| Q1 2026 |
| Q4 2025 |
| Q3 2025 | ||||||||||
|
|
|
|
|
|
|
|
|
| ||||||||||
Net income, as reported | $ | (1,173 | ) |
| $ | 963 |
|
| $ | 6,318 |
|
| $ | 4,132 |
|
| $ | 4,578 |
|
Adjustments: |
|
|
|
|
|
|
|
|
| ||||||||||
Interest income, net |
| (414 | ) |
|
| (372 | ) |
|
| (375 | ) |
|
| (552 | ) |
|
| (564 | ) |
Provision for income taxes |
| — |
|
|
| 106 |
|
|
| 417 |
|
|
| 292 |
|
|
| 222 |
|
Depreciation |
| 115 |
|
|
| 117 |
|
|
| 116 |
|
|
| 139 |
|
|
| 157 |
|
Amortization of intangibles |
| 175 |
|
|
| 174 |
|
|
| 175 |
|
|
| 60 |
|
|
| 38 |
|
Noncash lease expense |
| 183 |
|
|
| 179 |
|
|
| 173 |
|
|
| 169 |
|
|
| 164 |
|
Share-based compensation |
| 1,522 |
|
|
| 1,723 |
|
|
| 1,716 |
|
|
| 1,748 |
|
|
| 1,756 |
|
Severance and restructuring |
| 47 |
|
|
| 144 |
|
|
| 79 |
|
|
| 53 |
|
|
| 10 |
|
Gain on settlement of royalty obligation (1) |
| — |
|
|
| — |
|
|
| — |
|
|
| (1,983 | ) |
|
| — |
|
Gain on sale of operating segment (2) |
| — |
|
|
| 3 |
|
|
| (4,784 | ) |
|
| — |
|
|
| — |
|
Adjusted EBITDA | $ | 455 |
|
| $ | 3,037 |
|
| $ | 3,835 |
|
| $ | 4,058 |
|
| $ | 6,361 |
|
(1) Represents a gain related to the settlement of royalty obligations from a settlement agreement with | |||||||||||||||||||
(2) Represents a gain related to the sale of the Company’s Analytical Reference Standards and Services operating segment. | |||||||||||||||||||
Non-GAAP Financial Information:
To supplement Niagen Bioscience’s unaudited financial data presented in accordance with generally accepted accounting principles (GAAP), the Company has presented Adjusted EBITDA, a non-GAAP financial measure.
Adjusted EBITDA is defined as net income before (a) interest, (b) provision for income taxes, (c) depreciation, (d) amortization, (e) non-cash share-based compensation costs, (f) severance and restructuring expense and (g) other infrequent items, including gains recognized related to the sale of an operating segment and a royalty settlement. While
Non-GAAP financial measures are not prepared in accordance with, or an alternative for, generally accepted accounting principles in
View source version on businesswire.com: https://www.businesswire.com/news/home/20261104153325/en/
Investor Relations
1 (212) 896-1254
Niagen@kcsa.com
Media Relations
Senior Director of Media Relations & Partnerships
+1 (310) 405-5227
Kendall.Knysch@NiagenBio.com
Source: